Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival-Reference-Cited by-同舟云学术

Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival

Published:2018-05-10 Issue:33 Volume:37 Page:4489-4504
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Baker Andrew,Wyatt Debra,Bocchetta Maurizio,Li Jun,Filipovic Aleksandra,Green Andrew,Peiffer Daniel S.,Fuqua Suzanne,Miele Lucio^ORCID,Albain Kathy S.,Osipo Clodia

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/s41388-018-0251-y.pdf

Reference74 articles.

1. Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov. 2013;3:27–34.

2. Wachsman W, Cann AJ, Williams JL, Slamon DJ, Souza L, Shah NP, et al. HTLV x gene mutants exhibit novel transcriptional regulatory phenotypes. Science. 1987;235:674–7.

3. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14:320–68.

4. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676–85.

5. Untch M, Fasching PA, Konecny GE, Hasmuller S, Lebeau A, Kreienberg R, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011;29:3351–7.

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Furin, ADAM, and γ-secretase: Core regulatory targets in the Notch pathway and the therapeutic potential for breast cancer;Neoplasia;2024-11

2. Competing endogenous RNAs regulatory crosstalk networks: The messages from the RNA world to signaling pathways directing cancer stem cell development;Heliyon;2024-08

3. Notch3 as a novel therapeutic target for the treatment of ADPKD by regulating cell proliferation and renal cyst development;Biochemical Pharmacology;2024-06

4. Elevated histone deacetylase 10 expression promotes the progression of clear cell renal cell carcinoma by Notch-1-PTEN signaling axis;Discover Oncology;2024-05-11

5. Inhibition of γ-secretase/Notch pathway as a potential therapy for reversing cancer drug resistance;Biochemical Pharmacology;2024-02